二甲双胍和瑞格列奈对糖尿病慢性肾脏疾病患者血清转化生长因子–β1水平的影响

Effects of Metformin and Repaglinide on Serum Levels of Transforming Grouth Factor-1 in Patients with Chronic Kidney Disease of Diabetes Mellitus

目的:探讨二甲双胍和瑞格列奈对糖尿病慢性肾脏疾病患者血清转化生长因子–β1(TGF–β1)水平的影响。方法:将佛山市南海区中医院沙头分院收治的80例糖尿病慢性肾脏疾病患者当作观察对象,根据治疗方式的不同,将其随机分为二甲双胍治疗组(A组患者27例)、瑞格列奈治疗组(B组26例),以及二甲双胍联合瑞格列奈治疗组(C组27例)进行疗效对比。结果:联合用药组患者的整体改善效果要明显优于其他两组患者,组间比较,差异具有统计学意义(P<0.05)。经过各药物对血清TGF–β1水平影响的研究,结果显示,联合用药组较其他两组水平最优,组间比较,差异具有统计学意义(P<0.05)。结论:针对于糖尿病慢性肾脏疾病患者,联合用药治疗效果更加理想,同时两种药物均对血清TGF–β1水平产生作用。

Objective To investigate the effects of metformin and repaglinide on the levels of serum transforming grouth factor-1（TGF-β1） in diabetic patients with chronic kidney disease.Methods 80 patients with diabetic nephropathy were enrolled in this study.According to the different treatment methods,they were randomly divided into metformin treatment group（27 cases in group A）,repaglinide group（group B 26 group）,and metformin combined with repaglinide treatment group（group C,27 cases） were compared.Results The overall improvement effect of the combination group was significantly better than the other two groups,the difference between the two groups was statistically significant（P〈0.05）.The results showed that the combination group had the best level compared with the other two groups,and the difference was statistically significant（P〈0.05）.Conclusion For patients with chronic kidney disease of diabetes mellitus,the combination therapy is more effective,and both drugs have the effect on serum TGF-β1 level,which is worthy of clinical application.